numinus

Revive Therapeutics (RVV.C) joined the AdvisorShares Psychedelics ETF (PSIL.NYSE) today, in time for its launch, according to a press release.   If you’re not entirely sure what an ETF…
“In business, cash is oxygen” – Gary Vaynerchuk   Psychedelics is a cash-intensive business. Earlier in the week, I wrote about how clinical trials alone cost companies tens, sometimes…
Numinus Wellness (NUMI.V) announced that Health Canada has cleared their MAPS-sponsored single-arm, open-label safety and feasibility study evaluating MDMA-assisted therapy for post-traumatic stress disorder (PTSD). The study is being…
Numinus Wellness (NUMI.V) announced they are going to acquire Neurology Centre of Toronto (NCT), pursuant to a purchase agreement from July 2, 2021. To acquire the centre, Numinus will…
Numinus Wellness (NUMI.V) and Optimi Health (OPTI.C) announced they have submitted a pre-clinical trial application to Health Canada. The application was submitted through Impact Clinical Trials Accelerator at the…
“Life is too short to be small.” – Tim Ferriss, The 4-Hour Workweek Every psychedelics company starts its investor deck off with a fact about the quickly changing regulatory…
Numinus (NUMI.V)  is gaining somewhat of a cult-like following among retail investors.   People see an undervalued company with competitive advantages, and from an ethics standpoint, a company conducting…
Numinus Wellness (NUMI.V) closed its previously announced acquisition of psychedelic programming operation, Mindspace Psychology Services today. Mindspace Wellbeing, the operational arm of Mindspace Psychology Services, is a well-being organization…